Retrospective clinical trial experimentally validates glioblastoma genome-wide pattern of DNA copy-number alterations predictor of survival

Modeling of genomic profiles from the Cancer Genome Atlas (TCGA) by using recently developed mathematical frameworks has associated a genome-wide pattern of DNA copy-number alterations with a shorter, roughly one-year, median survival time in glioblastoma (GBM) patients. Here, to experimentally test this relationship, we whole-genome sequenced DNA from tumor samples of patients. We show that the patients represent the U.S. adult GBM population in terms of most normal and disease phenotypes. Intratumor heterogeneity affects ≈11% and profiling technology and reference human genome specifics affect <1% of the classifications of the tumors by the pattern, where experimental batch effects normally reduce the reproducibility, i.e., precision, of classifications based upon between one to a few hundred genomic loci by >30%. With a 2.25-year Kaplan–Meier median survival difference, a 3.5 univariate Cox hazard ratio, and a 0.78 concordance index, i.e., accuracy, the pattern predicts survival better than and independent of age at diagnosis, which has been the best indicator since 1950. The prognostic classification by the pattern may, therefore, help to manage GBM pseudoprogression. The diagnostic classification may help drugs progress to regulatory approval. The therapeutic predictions, of previously unrecognized targets that are correlated with survival, may lead to new drugs. Other methods missed this relationship in the roughly 3B-nucleotide genomes of the small, order of magnitude of 100, patient cohorts, e.g., from TCGA. Previous attempts to associate GBM genotypes with patient phenotypes were unsuccessful. This is a proof of principle that the frameworks are uniquely suitable for discovering clinically actionable genotype–phenotype relationships.

[1]  O. Alter,et al.  GSVD- and tensor GSVD-uncovered patterns of DNA copy-number alterations predict adenocarcinomas survival in general and in response to platinum , 2019, APL bioengineering.

[2]  Orly Alter,et al.  Mathematically universal and biologically consistent astrocytoma genotype encodes for transformation and predicts survival phenotype , 2018, APL bioengineering.

[3]  J. Olsen,et al.  Molecular basis of Tousled-Like Kinase 2 activation , 2018, Nature Communications.

[4]  Andrea J. Liu,et al.  DNA Damage Follows Repair Factor Depletion and Portends Genome Variation in Cancer Cells after Pore Migration , 2017, Current Biology.

[5]  R. Elashoff,et al.  Human TERT promoter mutation enables survival advantage from MGMT promoter methylation in IDH1 wild-type primary glioblastoma treated by standard chemoradiotherapy , 2016, Neuro-oncology.

[6]  Jill S Barnholtz-Sloan,et al.  CBTRUS Statistical Report: Primary brain and other central nervous system tumors diagnosed in the United States in 2010–2014 , 2017, Neuro-oncology.

[7]  O. Alter,et al.  Platform-Independent Genome-Wide Pattern of DNA Copy-Number Alterations Predicting Astrocytoma Survival and Response to Treatment Revealed by the GSVD Formulated as a Comparative Spectral Decomposition , 2016, PloS one.

[8]  E. Miyaoka,et al.  A combination of TERT promoter mutation and MGMT methylation status predicts clinically relevant subgroups of newly diagnosed glioblastomas , 2016, Acta neuropathologica communications.

[9]  R. Schiff,et al.  Amplification of TLK2 Induces Genomic Instability via Impairing the G2–M Checkpoint , 2016, Molecular Cancer Research.

[10]  S. Grossman,et al.  Published glioblastoma clinical trials from 1980 to 2013: Lessons from the past and for the future. , 2016 .

[11]  Steven J. M. Jones,et al.  Molecular Profiling Reveals Biologically Discrete Subsets and Pathways of Progression in Diffuse Glioma , 2016, Cell.

[12]  Steven J. M. Jones,et al.  Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. , 2015, The New England journal of medicine.

[13]  Alexander R. Pico,et al.  Glioma Groups Based on 1p/19q, IDH, and TERT Promoter Mutations in Tumors. , 2015, The New England journal of medicine.

[14]  Orly Alter,et al.  Tensor GSVD of Patient- and Platform-Matched Tumor and Normal DNA Copy-Number Profiles Uncovers Chromosome Arm-Wide Patterns of Tumor-Exclusive Platform-Consistent Alterations Encoding for Cell Transformation and Predicting Ovarian Cancer Survival , 2015, PloS one.

[15]  Michael Hay,et al.  Clinical development success rates for investigational drugs , 2014, Nature Biotechnology.

[16]  Henry Brem,et al.  Establishing percent resection and residual volume thresholds affecting survival and recurrence for patients with newly diagnosed intracranial glioblastoma. , 2014, Neuro-oncology.

[17]  F. Collins,et al.  First FDA authorization for next-generation sequencer. , 2013, The New England journal of medicine.

[18]  D. Haussler,et al.  The Somatic Genomic Landscape of Glioblastoma , 2013, Cell.

[19]  V. P. Collins,et al.  Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics , 2013, Proceedings of the National Academy of Sciences.

[20]  M. Delorenzi,et al.  MGMT methylation analysis of glioblastoma on the Infinium methylation BeadChip identifies two distinct CpG regions associated with gene silencing and outcome, yielding a prediction model for comparisons across datasets, tumor grades, and CIMP-status , 2012, Acta Neuropathologica.

[21]  T. Cloughesy,et al.  Impact of 3,4-Dihydroxy-6-18F-Fluoro-l-Phenylalanine PET/CT on Managing Patients with Brain Tumors: The Referring Physician's Perspective , 2012, The Journal of Nuclear Medicine.

[22]  Orly Alter,et al.  GSVD Comparison of Patient-Matched Normal and Tumor aCGH Profiles Reveals Global Copy-Number Alterations Predicting Glioblastoma Multiforme Survival , 2012, PloS one.

[23]  Charles R. Johnson,et al.  Matrix Analysis, 2nd Ed , 2012 .

[24]  O. Alter,et al.  A Higher-Order Generalized Singular Value Decomposition for Comparison of Global mRNA Expression from Multiple Organisms , 2011, PloS one.

[25]  Ryan Mills,et al.  Comprehensive assessment of array-based platforms and calling algorithms for detection of copy number variants , 2011, Nature Biotechnology.

[26]  Tomas W. Fitzgerald,et al.  Origins and functional impact of copy number variation in the human genome , 2010, Nature.

[27]  Sharon J. Diskin,et al.  Copy number variation at 1q21.1 associated with neuroblastoma , 2009, Nature.

[28]  D. Busam,et al.  An Integrated Genomic Analysis of Human Glioblastoma Multiforme , 2008, Science.

[29]  Joshua M. Korn,et al.  Comprehensive genomic characterization defines human glioblastoma genes and core pathways , 2008, Nature.

[30]  Santosh Kesari,et al.  Malignant gliomas in adults. , 2008, The New England journal of medicine.

[31]  Th. Boveri,et al.  Concerning the Origin of Malignant Tumours , 2008 .

[32]  Elizabeth Eisenhauer,et al.  Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3. , 2008, The Lancet. Oncology.

[33]  J. Lupski,et al.  Genomic rearrangements and sporadic disease , 2007, Nature Genetics.

[34]  Shmuel Friedland,et al.  A New Approach to Generalized Singular Value Decomposition , 2005, SIAM J. Matrix Anal. Appl..

[35]  D. Botstein,et al.  Gene expression profiling reveals molecularly and clinically distinct subtypes of glioblastoma multiforme. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[36]  Ivan Smirnov,et al.  Array Comparative Genomic Hybridization Identifies Genetic Subgroups in Grade 4 Human Astrocytoma , 2005, Clinical Cancer Research.

[37]  Martin J. van den Bent,et al.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.

[38]  R. Mirimanoff,et al.  MGMT gene silencing and benefit from temozolomide in glioblastoma. , 2005, The New England journal of medicine.

[39]  K. Kurisu,et al.  O6-Alkylguanine-DNA alkyltransferase activity of human malignant glioma and its clinical implications , 2005, Journal of Neuro-Oncology.

[40]  M. Wigler,et al.  Circular binary segmentation for the analysis of array-based DNA copy number data. , 2004, Biostatistics.

[41]  Allan H Friedman,et al.  Phase II trial of gefitinib in recurrent glioblastoma. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  D. Botstein,et al.  Generalized singular value decomposition for comparative analysis of genome-scale expression data sets of two different organisms , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[43]  G. Boulianne,et al.  Identification of a novel family of putative methyltransferases that interact with human and Drosophila presenilins. , 2001, Gene.

[44]  C. Sawyers,et al.  Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. , 2001, The New England journal of medicine.

[45]  A. Friedman,et al.  Comparative genetic patterns of glioblastoma multiforme: potential diagnostic tool for tumor classification. , 2000, Neuro-oncology.

[46]  Robert A. Weinberg,et al.  Creation of human tumour cells with defined genetic elements , 1999, Nature.

[47]  Bert Vogelstein,et al.  Uncoupling of S phase and mitosis induced by anticancer agents in cells lacking p21 , 1996, Nature.

[48]  C. Sommer,et al.  Clinically distinct subgroups of glioblastoma multiforme studied by comparative genomic hybridization. , 1996, Laboratory investigation; a journal of technical methods and pathology.

[49]  K. Herrup,et al.  Targeted disruption of mouse EGF receptor: effect of genetic background on mutant phenotype. , 1995, Science.

[50]  D. Nelson,et al.  Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. , 1993, Journal of the National Cancer Institute.

[51]  S. Smith,et al.  Diagnosis of chronic myeloid and acute lymphocytic leukemias by detection of leukemia-specific mRNA sequences amplified in vitro. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[52]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[53]  M. Netsky,et al.  The longevity of patients with glioblastoma multiforme. , 1950, Journal of neurosurgery.